Callan Capital LLC Makes New $2.12 Million Investment in Edwards Lifesciences Co. (NYSE:EW)

Callan Capital LLC bought a new position in Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, Holdings Channel reports. The firm bought 27,756 shares of the medical research company’s stock, valued at approximately $2,116,000.

Several other hedge funds have also made changes to their positions in the company. Turtle Creek Wealth Advisors LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth $34,000. Operose Advisors LLC raised its stake in Edwards Lifesciences by 247.0% in the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after buying an additional 452 shares during the last quarter. SRS Capital Advisors Inc. raised its stake in Edwards Lifesciences by 292.6% in the third quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after buying an additional 474 shares during the last quarter. NBC Securities Inc. purchased a new stake in Edwards Lifesciences in the third quarter valued at about $52,000. Finally, ORG Partners LLC purchased a new stake in Edwards Lifesciences in the third quarter valued at about $66,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the completion of the sale, the vice president now owns 173,849 shares of the company’s stock, valued at $16,049,739.68. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction on Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the completion of the sale, the vice president now directly owns 173,849 shares of the company’s stock, valued at $16,049,739.68. The disclosure for this sale can be found here. Insiders sold a total of 194,004 shares of company stock valued at $17,166,254 over the last quarter. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Stock Performance

NYSE EW opened at $86.43 on Friday. The company has a market cap of $52.02 billion, a PE ratio of 37.25, a price-to-earnings-growth ratio of 4.36 and a beta of 1.05. The stock’s 50 day simple moving average is $90.28 and its 200-day simple moving average is $78.85. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 23.34% and a net margin of 23.01%. The firm had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on EW. Piper Sandler increased their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a research note on Friday. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Oppenheimer increased their price objective on Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, March 18th. Stifel Nicolaus increased their price objective on Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a report on Friday. Finally, Citigroup increased their price objective on Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $93.33.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.